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Background: Making a diagnosis of HIV infection 
in children aged less than 18 months remains a 
challenge in low resource settings like Zambia due 
to the limited availability of gold standard testing 
with HIV DNA PCR. Clinicians in rural areas have 
to depend on clinical diagnosis to start HAART as 
they wait for the dry blood spot (DBS) for DNA PCR 
results sent from the urban centers. 
Methods: This descriptive cross-sectional study was 
performed at the University Teaching Hospital, 
Lusaka, Zambia. 299 HIV-exposed children aged 
less than 18 months were enrolled following a 
consent procedure. Patients were evaluated for HIV 
infection based on the World Health Organization's 
presumptive diagnostic criteria (WHO-PDC), 
integrated management of childhood illnesses 
(IMCI) criteria, select physical exam abnormalities, 
and CD4% and findings were compared with HIV-
DNA PCR results. 
Results: Of the 299 exposed patients analyzed, 
111(37%) were found to be HIV-positive by DNA 
PCR. The median CD4% in the infected children 
was 18%. WHO-PDC used on its own had 23% 
sensitivity (95% CI 17-32%) and 93% specificity 
(88-96%), respectively, whereas IMCI criterion had 
10% sensitivity (6-17%) and 97% specificity (94-
99%), respectively. Multivariate analysis was used 
to identify the most sensitive predictors when 
combined with the WHO-PDC and IMCI criterion. 
WHO-PDC with CD4% improved the sensitivity to 
77% (68-83%) with a specificity of 83% (77-88%), 
positive predictive value (PPV) of 73% (64-80%) 
and negative predictive value (NPV) of 86% (80-
90%). IMCI with CD4% improved sensitivity to 
80% (71-87%) with a specificity of 88% (82-92%), 
PPV 78% (69-85%) and NPV 89% (84-93%). The 
addition of individual physical exam findings 
without CD4% improved the sensitivity of WHO-
PDC only modestly. When the WHO-PDC, 
rd
weight<3  percentile, hepatomegaly, splenomegaly, 
lymphadenopathy and CD4% were combined, the 
sensitivity improved to 85% (77-90%), specificity 
63% (56-70%), PPV 58% (50-65%) and NPV of 
88% (81-92%).
Conclusion: The WHO-PDC clinical algorithm can 
be improved when combined with a CD4% <25% in 
children less than 12 months of age and CD4% 
<20% in those between 12 and 18 months.  
INTRODUCTION 
The introduction of combination highly active 
antiretroviral therapy (HAART) has led to improved 
outcomes in HIV-infected infants and young 
children worldwide. In sub-Sahara Africa, countries 
including Zambia have adopted the WHO 
Antiretroviral Therapy guidelines when initiating 
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HAART. The 2008 WHO guidelines recommend 
that HAART should be started in all infants with a 
1 ,  2 ,  3
positive HIV DNA PCR result.  This 
recommendation came from studies showing that in 
the absence of HAART, there is 30% one-year 
4,5
mortality and 50% two-year mortality.  However, in 
resource-poor areas where DNA PCR is not readily 
available, infant HIV diagnosis and treatment are 
frequently delayed while awaiting PCR results from 
dried blood spots (DBS) sent to a central referral 
6,7laboratory.  In light of these limitations, WHO 
encourages presumptive diagnosis and treatment in 
children aged less than 18 months with confirmation 
3 of HIV status as soon as possible.
To facilitate this process, WHO introduced 
presumptive diagnostic criteria (WHO-PDC) based 
on the WHO clinical paediatric HIV staging system. 
In addition to the WHO-PDC criteria, other 
algorithms have been proposed to clinically identify 
HIV-positive infants and children. The integrated 
management of childhood illness (IMCI) program is 
a WHO and UNICEF strategy aimed at improving 
both case management skills of primary health care 
providers and community health practitioners for 
children under 5 years old in places where there are 
8  
inadequate health care facilities.
There is insufficient data available regarding these 
clinical algorithms in conjunction with CD4% or 
other parameters, and WHO encourages researchers 
3
to validate approaches.  This study evaluated the 
performance of the WHO clinical algorithm for 
presumptive diagnosis of HIV infection in HIV-
exposed infants and young children. We also 
evaluated whether or not the addition of CD4% or 
specific clinical exam findings improves the 
accuracy of the WHO-PDC. 
METHODS 
Study Design
We conducted a prospective cross-sectional study at 
the University Teaching Hospital (UTH), a tertiary-
care referral hospital in Lusaka, Zambia, with 450 
paediatric in-patient beds. 
Patients and data collection 
All HIV-exposed children aged 18 months or 
younger admitted to the UTH paediatric wards 
during a six month period in 2009 were screened for 
the study. HIV exposure was defined as a positive 
rapid HIV test using the Determine HIV-1/2 (Abbott 
Diagnostic Division, Hoofddorp, The Netherlands) 
with confirmation by a second ELISA test, the 
Unigold HIV Test (Trinity BioTech, Bray, Ireland). 
Infants with known HIV DNA PCR results were 
excluded from the study. Critically ill infants, 
defined as those who required some form of organ 
support, including oxygen supplementation, were 
also excluded due to social constraints. Trained 
study assistants identified eligible participants and, 
following a detailed informed consent process, a 
questionnaire was administered to all consenting 
participants and 2 milliliters of blood drawn for 
CD4% and DBS card preparation for DNA PCR 
testing. All children were examined by a paediatrics 
Registrar (KMK) who made the final decision 
regarding physical findings. CD4% was estimated 
TMusing the BD FACSCalibur  flow cytometer. HIV 
DNA PCR was performed with a DBS-based 
qualitative technique using the Roche AMPLICOR 




We used the WHO presumptive diagnosis criterion 
(WHO-PDC) for infants as follows: 
•Confirmed positive HIV antibody test in 
the infant AND 
- Presence of any AIDS indicator 
condition, OR 
- Symptomatic infant with two or more 
of the following: oral thrush, severe 
pneumonia and severe sepsis
Other factors that WHO lists in support of the 
diagnosis of severe HIV disease (recent HIV-related 
maternal death, CD4% <20% in children <18 
months but >12 months old, CD4% <25% in 
children <12 months old) are not part of the formal 
algorithm, and were considered separately. 
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IMCI CRITERIA 
We used the adapted IMCI guidelines for referral in 
Zambia of children under 5 years old suspected to 
have HIV. These guidelines include seropositive 
mother and child and three (3) or more of the 
following:
•chronic otitis media
•low weight for age or growth faltering or 
history of weight loss
•recurrent pneumonia
•persistent diarrhea
•lymphadenopathy in more than two sites 
(neck, axilla or groin)
•oral thrush
•parotid enlargement for more than 14 days
•health problems in sibling or other parent
Analysis
The data collected was entered in Microsoft Access 
database and analyzed with SAS version 9.1.3. 
Analysis included calculation of sensitivity, 
specificity, positive and negative predictive value of 
WHO-PDC, IMCI criteria and CD4% and other 
selected clinical signs including the age of the 
patient. HIV DNA PCR result was used as the gold 
standard for presence of HIV disease. WHO-PDC 
and IMCI criteria are described below. In accordance 
with WHO criteria, CD4% cutoffs for positive test 
were set at <25% for children less than 12 months of 
age and <20% for children 12 to <18 months. 
Predictors of HIV infection were identified using 
multivariate analysis. T-test to compare the median 
CD4% in those with and without confirmed HIV was 
also applied. This study was approved by the ethics 
committees of the University of Zambia and the 
University of Alabama in Birmingham (UAB) and 
informed consent was obtained from caregivers of 
all patients recruited. 
RESULTS
Enrollment
Between May and November 2009, 6,816 children 
presented to the UTH, of whom 3,905 (57%) were 
children less than 18 months of age (Figure 1). 737 
children <18 months old (19%) tested positive by 
rapid HIV tests. 422 of the 737 children were 
excluded for the following reasons: known HIV 
DNA PCR results, refused consent, were critically 
ill, were brought by a guardian unfamiliar with the 
child's history, or were discharged before they could 
be consented. 315 children were enrolled into the 
study. Of these, 16 were excluded from final data 
analysis due to incomplete laboratory results. 
Patient characteristics 
Biological mothers accounted for 94% of the 
respondents. The majority of caregivers were aged 
between 25-35 years (57.4%) and unemployed 
(61%). 227 (75.9%) children enrolled in the study 
were under 6 months of age. Only 13 (4.3%) of the 
children were aged between 12-18 months. 
Pneumonia (41.8%) and sepsis (35.1%) were the 
most common admission diagnoses. 118 (49.0%) 
children were receiving co-trimoxazole for 
Pneumocystis Jerovici prophylaxis as outpatients. 
Baseline characteristics of the children are 
summarized in Table 1. 
Figure 1 
       3905 Tested for HIV











299 Included in final analysis
16 missing lab results
111 (37%) DNA PCR 
Positive
188 (63%) DNA PCR 
Negative
422 Excluded:    
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Table 1:  Baseline characteristics of 299 children 
included
All values reported as n (%) except CD4%
† All 13 children >12 months of age were DNA PCR positive
^ Total is more than 100% due to presence of concurrent 
diagnoses.
*PMTCT – Prevention of mother-to-child transmission; 
PMTCT information available for 282 mother-infant pairs
HIV results 
Positive HIV DNA PCR was noted in 111 (37%) of 
the 299 infants analyzed. The proportion of HIV-
exposed children with positive PCR increased with 
age (Table 2). All of the 13 children between 12 and 
18 months of age tested PCR positive. Median 
CD4% was 18% (IQR 12-26%) among HIV-
positive children and 40% (IQR 31-50%) in HIV-
negative children. Antiretroviral PMTCT (Odds 
ratio 0.62; 95% CI 0.37 - 1.03) and breastfeeding 
(OR 1.32; 95% CI 0.79 - 2.21) were not significantly 
associated with HIV infection. 
Performance of Diagnostic Algorithms 
Sensitivities, specificities, and positive and negative 
predictive values of WHO-PDC and the other 
various diagnostic algorithms are displayed in 
Tables 2 and 3. Ninety-five percent confidence 
intervals are included in the tables. The sensitivity of 
the WHO-PDC was 23% and the specificity 93%. 
WHO-PDC performance did not vary with age 
(Table 2). When combined with CD4%, WHO-PDC 
sensitivity increased to 77%, though specificity 
dropped to 83%. CD4% alone had a sensitivity and 
specificity of 74% and 88%, respectively. 
The following physical exam findings when 
individually added to the WHO-PDC slightly 
improved the sensitivity: splenomegaly (35%, 
rd
95%CI 26-45%), weight <3  percentile (36%, 
95%CI 27-46%), hepatomegaly (40%, 95%CI 31-
49%), and lymphadenopathy (41%, 95% CI 33-
51%). Specificities ranged from 85-91%. The 
addition of all four examination findings to WHO-
PDC, and CD4% yielded the highest sensitivity 
(85%) with specificity of 64%, positive and negative 
predictive values of 57% and 86%, respectively (see 
Table 3). The addition of CD4% to IMCI criteria 
raised its sensitivity from 10% to 80% but lowered 
the specificity to 88%. Receiver operating 
characteristic (ROC) curves for selected algorithms 
are displayed in Figure 2. Area under the ROC 
curves was greatest for IMCI plus CD4% (0.84). 
DISCUSSION 
This study assessed the performance of the WHO-
PDC for diagnosing HIV in children less than 18 
months of age. WHO-PDC was compared with the 
DNA PCR, which is the current gold standard for the 
diagnosis of HIV in children younger than 18 
months. The HIV prevalence was 37% in this group 
of 299 seropositive children. The WHO-PDC was 
found to be only 23% sensitive, with a specificity of 
93%. A low CD4% on its own or combined with the 
WHO-PDC was found to be highly predictive of 
HIV infection. Clinical signs were 33% to 41% 
sensitive when combined with WHO-PDC with 
specificities above 85%. Use of the IMCI guidelines 
also showed an increased sensitivity (80%, from 
10%) when combined with the CD4%. 
Age 
<6 months 
  6 to <12 months 
  12 to 18 months 
 
227 (75.9) 
 59 (19.7) 
 13 (4.3) 
Male 159 (53.2) 
Mother deceased    6 (2.0) 
Sibling deceased   67 (22.5) 
CD4%, median (IQR) 
<12 months of age 
   12-18 months of age† 
 
  32 (20-44) 
  20 (13-27) 
Hospital diagnosis^ 
  Pneumonia 
  Sepsis 
  Acute diarrheal disease 
  Oral thrush 
  Excessive irritability/fever 
  Severe malnutrition 
  URTI 
  Meningitis 
  Chronic diarrhea 




 44 (14.7)  
35 (11.7)  
19 (6.4) 
   7 (2.3) 
   7 (2.3) 
   6 (2.0) 
4 (1.3) 
27 (9.0) 
Received antiretrovirals for 
PMTCT* 
  None 
  Mother only 
  Mother and infant 
 
122 (43.3) 
  21 (7.4) 
139 (49.3) 
Breastfed 181 (60.5) 
Co-trimoxazole prophylaxis 118 (49.0) 
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The sensitivity of the WHO-PDC algorithm (23%) 
was markedly lower than reported in other studies. 
In Kenya, Inwani et al found the WHO-PDC to be 
943% sensitive and 88% specific.  Peltier et al 
evaluated the algorithm in Rwanda and documented 
10
77% sensitivity but only 63% specificity.  Both of 
these studies had higher detection rates for stage 4 
conditions. In Rwanda, 52% of all patients had 
severe malnutrition, a stage 4 diagnosis that was 
relatively uncommon in our study population. A 
notable difference in our study design that likely 
contributed to the decreased sensitivity of WHO-
PDC was the exclusion of critically ill infants. A 
non-critically ill population such as ours is less 
likely to present with multiple PDC criteria despite 
being HIV-positive, and it is possible that many of 
the HIV-positive infants who presented with stage 4 
diseases were excluded because of critical illness.  
 
Table 2. Performance of WHO-PDC for HIV-1 infections in infants by age 




Sensitivity (95% CI) Specificity (95% CI) 
0 to <6  227 57 (25) 0.21 (0.11 - 0.34) 0.93 (0.88 - 0.96) 
6 to <12  59 41 (69) 0.24 (0.12 - 0.40) 0.89 (0.65 - 0.99) 
12 to <18  13  13 (100) 0.23 (0.05 - 0.54) - 
All Children 299 111 (37) 0.23 (0.17 - 0.32) 0.93 (0.88 - 0.96) 
Table 3.Sensitivity, Specificity and predictive values for HIV-1 infection in infants using Different 
Algorithms 
Criteria Sensitivity Specificity PPV NPV 
WHO-PDC 0.23 (0.17-0.32) 0.93 (0.88-0.96) 0.65 (0.50-0.78) 0.67 (0.61-0.73) 
CD4%* 0.74 (0.65-0.82) 0.88 (0.83-0.92) 0.77 (0.67-0.84) 0.87 (0.81-0.91) 
WHO –PDC+ CD4%* 0. 77 (0.68-0.83) 0.83 (0.77-0.88) 0.73 (0.64-0.80) 0.86 (0.80-0.90) 
WHO-PDC + CD4%* 
+ clinical findings** 
0. 85 (0.77-0.90) 0.63 (0.56-0.70) 0.58 (0.50-0.65) 0.88 (0.81-0.92) 
IMCI 0.10 (0.06-0.17) 0.97 (0.94-0.99) 0.69 (0.44-0.86) 0.65 (0.59-0.70) 
IMCI + CD4%* 0. 80 (0.71-0.87) 0.88 (0.82-0.92) 0.78 (0.69-0.85) 0.89 (0.84-0.93) 
 
95% confidence intervals in parentheses.
* CD4 cutoffs: <25% if age <12 months, <20% if 12-18 months
rd**Clinical findings = weight <3  percentile, hepatomegaly, splenomegaly, lymphadenopathy 
The median CD4% in HIV-infected children was 
18%, compared with 40% in the HIV-negative 
children. Various studies have shown that CD4% is 
lower in HIV-1-infected children, and a low CD4% is 
highly predictive of disease progression, even in 
11-12 
young infants. Our study roughly agreed with an 
earlier study done in Zambia that showed a median 
CD4% of 35% in HIV-negative children less than 2 
13 
years old. We used CD4% cut-offs according to 
WHO immunological criteria for severe 
immunodeficiency by age:less than 25% in those 
under 12 months and less than 20% in those >12 
3months but <18 months.  Based on these cutoffs, 
CD4% used alone or in combination with the WHO-
PDC was found to strongly predict the chances of a 
positive DNA PCR. Analyzing WHO-PDC and 
CD4% criteria would have identified 83 (75%) of the 
111 HIV-infected children without having to wait for 
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DNA PCR results, with only 30 false positives. The 
performance of CD4% in our study exceeded that 
seen in Kenya (81% sensitive, 39% specific) and 
Rwanda (56% sensitive, 79% specific). CD4 
percentages were generally higher in the Rwandan 
study despite severe malnutrition. We could not 
establish if the prevailing infections in our study had 
a marked reductive effect on the T-lymphocytes. It 
would have also been useful to assess CD4:CD8 
ratios, which have been a more sensitive predictor 
of HIV infection in exposed children in other 
14-17 areas.
Although clinical exam abnormalities, such as 
nappy rash, lymphadenopathy, and hepatomegaly, 
18
are more common in HIV-infected children , 
individual exam abnormalities, added to WHO-
PDC, were not particularly sensitive indicators of 
rd
HIV infection. When the WHO-PDC, weight <3  
percentile,  hepatomegaly, splenomegaly, 
lymphadenopathy and CD4% were combined, the 
sensitivity improved to 85%, with a specificity of 
63%. However, the area under the ROC curve was 
lower with this combination than with WHO-PDC 
plus CD4 count or with CD4 count alone. 
Although WHO-PDC criteria were insensitive, 
IMCI guidelines were even worse when used alone, 
yielding 10% sensitivity when compared to DNA 
PCR. In combination with CD4%, IMCI sensitivity 
improved to 80% with a specificity of 88%. Thus, 
the IMCI tool in conjunction with CD4% would be 
useful in situations where caregivers are more 
familiar with the IMCI guidelines as opposed to the 
WHO-PDC. In fact, in our study IMCI plus CD4% 
was the best performing algorithm as measured by 
area under ROC curve. 
There were several limitations to this study. As 
previously mentioned, the exclusion of critically ill 
patients likely diminished the sensitivity of the 
WHO-PDC. Additionally, the study site was a 
tertiary care referral hospital and thus the study 
population was not representative of the general 
population seen at primary care settings.  
Despite these limitations, several conclusions can 
be drawn from our findings. The addition of one or 
multiple physical exam findings increases the 
sensitivity of the WHO-PDC only marginally. 
Adding CD4% testing to the WHO-PDC improves 
the sensitivity of the algorithm considerably but is 
not any better than CD4% alone. Clinical 
diagnostic algorithms are generally not reliable 
enough to conclusively diagnose HIV infection. 
Improving the access to dry blood spot PCR with 
timely reporting of results would be the optimal 
means of addressing the problem of early diagnosis 
in infants. In settings where timely PCR results are 
not possible but CD4% is available, we 
recommend the use of CD4% in any diagnostic 
algorithm. 
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